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Despite neoadjuvant chemotherapy, few patients with colorectal cancer liver
metastases (CRLM) are eligible for liver resection. The aim of the present study
was to investigate the efficacy of introperative radiofrequency ablation (IRFA) in
the treatment of unresectable CRLM.
Methods
Patients with unresectable metastases confined to the liver were eligible for this
prospective, multicentre phase II study conducted between 2003 and 2008. They
received IRFA treatment either with or without parenchymal resection, and
underwent clinical and pathological examinations. The primary endpoint was
complete hepatic response at 3 months. Overall, event-free and local progression-
free survival, morbidity and quality of life were also examined.
Results
Fifty-two patients were included, all of whom received neoadjuvnt chemotherapy.
They had a median of 5 (range 1–13) metastases, mostly bilateral or recurrent. A
complete hepatic response was observed in 39 patients (75 (95 per cent
confidence interval (c.i.) 61 to 86) per cent). Of ten patients with hepatic
recurrence at 3 months, two relapses were at the site of ablation. Median follow-up
was 2·9 years (95 per cent c.i. 2·5 to 3·6) years. The 1-year local progression-free
survival rate was 46 (95 per cent c.i. 32 to 59) per cent, the 3-year event-free
survival rate was 10 (95 per cent c.i. 21 to 64) per cent. Twenty patients had
postoperative complications, including one death. Quality of life increased over
time for patients without disease progression.
Conclusion
IRFA, either with or without resection, is a promising treatment option for patients
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